85 related articles for article (PubMed ID: 15741203)
1. Combination therapy with sirolimus (rapamycin) and tacrolimus (FK-506) in treatment of refractory minimal change nephropathy, a clinical case report.
Patel P; Pal S; Ashley C; Sweny P; Burns A
Nephrol Dial Transplant; 2005 May; 20(5):985-7. PubMed ID: 15741203
[No Abstract] [Full Text] [Related]
2. What does the CONVERT trial really tell us about conversion from calcineurin inhibitors to sirolimus?
Hanto DW; Chudzinski R
Transplantation; 2009 Jan; 87(2):164-5. PubMed ID: 19155968
[No Abstract] [Full Text] [Related]
3. Sirolimus conversion for renal preservation in liver transplantation: not so fast.
Jensen GS; Wiseman A; Trotter JF
Liver Transpl; 2008 May; 14(5):601-3. PubMed ID: 18433068
[No Abstract] [Full Text] [Related]
4. Considerations in sirolimus use in the early and late post-transplant periods.
Patel SJ; Elliott EN; Knight RJ; Gaber LW; Gaber AO
Expert Opin Drug Saf; 2009 Jul; 8(4):421-34. PubMed ID: 19522662
[TBL] [Abstract][Full Text] [Related]
5. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
DuBay D; Smith RJ; Qiu KG; Levy GA; Lilly L; Therapondos G
Liver Transpl; 2008 May; 14(5):651-9. PubMed ID: 18433069
[TBL] [Abstract][Full Text] [Related]
6. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
[TBL] [Abstract][Full Text] [Related]
7. Nephrotoxicity of ciclosporin A: short-term gain, long-term pain?
Chapman JR; Nankivell BJ
Nephrol Dial Transplant; 2006 Aug; 21(8):2060-3. PubMed ID: 16728428
[No Abstract] [Full Text] [Related]
8. Different renal toxicity profiles in the association of cyclosporine and tacrolimus with sirolimus in rats.
Lloberas N; Torras J; Alperovich G; Cruzado JM; Giménez-Bonafé P; Herrero-Fresneda I; Franquesa Ml; Rama I; Grinyó JM
Nephrol Dial Transplant; 2008 Oct; 23(10):3111-9. PubMed ID: 18469305
[TBL] [Abstract][Full Text] [Related]
9. Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease.
Jurado M; Vallejo C; Pérez-Simón JA; Brunet S; Ferra C; Balsalobre P; Pérez-Oteyza J; Espigado I; Romero A; Caballero D; Sierra J; Ribera JM; Díez JL
Biol Blood Marrow Transplant; 2007 Jun; 13(6):701-6. PubMed ID: 17531780
[TBL] [Abstract][Full Text] [Related]
10. Amiodarone-sirolimus/tacrolimus interaction in a pediatric heart transplant patient.
Nalli N; Stewart-Teixeira L; Dipchand AI
Pediatr Transplant; 2006 Sep; 10(6):736-9. PubMed ID: 16911499
[TBL] [Abstract][Full Text] [Related]
11. [New developments in immunosuppressive therapy].
Hopt UT
Kongressbd Dtsch Ges Chir Kongr; 2001; 118():620-3. PubMed ID: 11824327
[TBL] [Abstract][Full Text] [Related]
12. Impairment of renal function after islet transplant alone or islet-after-kidney transplantation using a sirolimus/tacrolimus-based immunosuppressive regimen.
Andres A; Toso C; Morel P; Demuylder-Mischler S; Bosco D; Baertschiger R; Pernin N; Bucher P; Majno PE; Bühler LH; Berney T
Transpl Int; 2005 Nov; 18(11):1226-30. PubMed ID: 16221151
[TBL] [Abstract][Full Text] [Related]
13. Sirolimus, Tacrolimus and Zotarolimus eluting stents to treat bifurcated lesions: a 7-month clinical outcome comparison.
Brugaletta S; Burzotta F; Trani C; Todaro D; Talarico G; Porto I; Leone AM; Niccoli G; Mazzari MA; Mongiardo R; Schiavoni G; Crea F
Minerva Cardioangiol; 2008 Feb; 56(1):35-42. PubMed ID: 18432167
[TBL] [Abstract][Full Text] [Related]
14. Early renal benefit of rapamycin combined with reduced calcineurin inhibitor dose in pediatric heart transplantation patients.
Balfour IC; Srun SW; Wood EG; Belsha CW; Marshall DL; Ferdman BR
J Heart Lung Transplant; 2006 May; 25(5):518-22. PubMed ID: 16678029
[TBL] [Abstract][Full Text] [Related]
15. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
[TBL] [Abstract][Full Text] [Related]
16. Successful use in lung transplantation of an immunosuppressive regimen aimed at reducing target blood levels of sirolimus and tacrolimus.
Villanueva J; Boukhamseen A; Bhorade SM
J Heart Lung Transplant; 2005 Apr; 24(4):421-5. PubMed ID: 15797743
[TBL] [Abstract][Full Text] [Related]
17. Limited utility of rapamycin in severe, refractory Wegener's granulomatosis.
Koening CL; Hernández-Rodríguez J; Molloy ES; Clark TM; Hoffman GS
J Rheumatol; 2009 Jan; 36(1):116-9. PubMed ID: 19012360
[TBL] [Abstract][Full Text] [Related]
18. Tacrolimus as a steroid-sparing agent for adults with steroid-dependent minimal change nephrotic syndrome.
Li X; Li H; Chen J; He Q; Lv R; Lin W; Li Q; He X; Qu L; Suya W
Nephrol Dial Transplant; 2008 Jun; 23(6):1919-25. PubMed ID: 17911091
[TBL] [Abstract][Full Text] [Related]
19. Recurrence of migraine with aura due to tacrolimus therapy in a liver transplant recipient successfully treated with sirolimus substitution.
Toth CC; Burak K; Becker W
Headache; 2005 Mar; 45(3):245-6. PubMed ID: 15836601
[TBL] [Abstract][Full Text] [Related]
20. Tacrolimus-associated optic neuropathy after pancreatic islet transplantation using a sirolimus/tacrolimus immunosuppressive regimen.
Kessler L; Lucescu C; Pinget M; Charton MN; Mutschler V; Wolf P; Berney T; Benhamou PY;
Transplantation; 2006 Feb; 81(4):636-7. PubMed ID: 16495816
[No Abstract] [Full Text] [Related]
[Next] [New Search]
